Grifols, S.A. and Aradigm Corp. have completed the transaction involving the exclusive, worldwide license for Aradigm’s formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE). Aradigm has completed Phase IIb trials in BE patients with Pulmaquin and Lipoquin and has been granted orphan drug designation for BE in the U.S. The companies will advance Aradigm’s inhaled ciprofloxacin formulation...